TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01503060
Drug: Lidocaine Placebo
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
Study: NCT01503060
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
Study: NCT03284294
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholecalciferol 2000 IU oral daily for 8 weeks
Study: NCT01870219
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
Study: NCT01870219
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine was given to 1mg/kg ıv bolus
Study: NCT01968720
Drug: CAT-2003
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01876732
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
Study: NCT03834129
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
Study: NCT03834129
Drug: sodium chloride 0.9%
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
Study: NCT00718419
Drug: Enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression.
Study: NCT04329611
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COVID19
Study: NCT00556361
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
Study: NCT00556361
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
Study: NCT00035425
Drug: linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg every 12 hours
Study: NCT00035425
Drug: vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
Study: NCT01785433
Drug: Tiotropium HFA BAI 4.5 mcg
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01785433
Drug: Tiotropium HFA BAI 9.0 mcg
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01002534
Drug: Vardenafil
Normalized name: Vardenafil
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal instillation of Vardenafil
Study: NCT01856595
Drug: PF-06291874
Normalized name: PF-06291874
DrugBank: PF-06291874 (DB15065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
Study: NCT00395252
Drug: Cetuximab (Erbitux®) and Gemcitabine
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion
Study: NCT01380106
Drug: Lenalidomide 15mg
Normalized name: LENALIDOMIDE 15MG CAP,ORAL
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
Study: NCT01380106
Drug: Lenalidomide 25mg
Normalized name: LENALIDOMIDE 25MG CAP,ORAL
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
Study: NCT00257387
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04346628
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
Study: NCT00314756
Drug: imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02106897
Drug: BIIB059 (litifilimab)
Normalized name: Immunoglobulin g1, anti-(human blood dendritic cell antigen 2) (human-mus musculus monoclonal biib059 .gamma.1-chain), disulfide with human-mus musculus monoclonal biib059 .kappa.-chain, dimer
DrugBank: Litifilimab (DB18864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Descriptions
Study: NCT01763905
Drug: Placebo to Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection
Study: NCT01763905
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet for oral administration
Study: NCT01763905
Drug: Placebo to Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet for oral administration
Study: NCT00878657
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
Study: NCT03926559
Drug: Morphine.
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
Study: NCT01597557
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 grams intravenous drip over 30 minutes
Study: NCT04527562
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
Study: NCT00429065
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002789
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002789
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00016874
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00016874
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00016874
Drug: triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02493816
Drug: Gene-modified autologous fibroblasts
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
Study: NCT01090089
Drug: Lenalidomide, Dexamethasone
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
Study: NCT01090089
Drug: Lenalidomide, Dexamethasone, PBSCT
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
Study: NCT02172521
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
Study: NCT01428063
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01428063
Drug: Asunaprevir
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT01428063
Drug: Pegylated interferon alfa-2a
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01428063
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02273440
Drug: BIIL 284 BS
Normalized name: BS-001
DrugBank: BS-001 (DB17415)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01260246
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pill, 100mg/daily for 6 months
Study: NCT00003445
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00986258
Drug: Tapentadol Prolonged Release
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached.
Study: NCT01014637
Drug: Amorolfine (Antifungal)
Normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Amorolfine for 36 weeks
Study: NCT01014637
Drug: RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
Study: NCT00978861
Drug: Hydrogen Peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whitening product syringe type
Study: NCT02902172
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
Study: NCT01260467
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 milligrams orally twice a day
Study: NCT02669004
Drug: Intermittent bolus epidural morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
Study: NCT02669004
Drug: continuous epidural morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
Study: NCT01727713
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open Label: Once-Daily formulation of aripiprazole flex dose regimine
Study: NCT03862079
Drug: Nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03862079
Drug: Piperacillin-Tazobactam
Normalized name: piperacillin-tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00313599
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00313599
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00330655
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00228254
Drug: vitamin A 10,000 IU per week
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02631135
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIS values were arranged 40-60 until the end of operation
Study: NCT02631135
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 microgram/kg infusion, no changes
Study: NCT02631135
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg iv for intubation, no changes
Study: NCT03741894
Drug: Iodoform
Normalized name: Iodoform
DrugBank: Iodoform (DB13813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
Study: NCT03741894
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
Study: NCT01753076
Drug: Ozanezumab
Normalized name: Ozanezumab
DrugBank: Ozanezumab (DB12891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanezumab injection solution
Study: NCT02918266
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine subcutaneous injection
Study: NCT02918266
Drug: TAK-071
Normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-071 DIC
Study: NCT02918266
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil over-encapsulated tablet
Study: NCT02918266
Drug: TAK-071 Placebo
Normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-071 placebo-matching DIC
Study: NCT02389816
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine tablets
Study: NCT02131948
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal spray
Study: NCT00074841
Drug: Sulfadoxine-Pyrimethamine/Chloroquine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01987310
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 20 mg per day for 6 months
Study: NCT02125721
Drug: Tiopronin 1g per day
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg PO BID x 7 days
Study: NCT02125721
Drug: Tiopronin 2g per day
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g PO BID x 7 days
Study: NCT01914419
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00995345
Drug: KRP-104
Normalized name: Krp-203 free base
DrugBank: Mocravimod (DB18151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00679679
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 750 mg BID for 4 months
Study: NCT00471536
Drug: pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 800 mg Given orally
Study: NCT00652431
Drug: Vytorin
Normalized name: Vytorin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
Study: NCT00652431
Drug: Niaspan
Normalized name: Niaspan
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
Study: NCT00300469
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily, 12 weeks, see Arm Description for dosage information
Study: NCT02125721
Drug: Tiopronin 3g per day
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5g PO BID x 7 days
Study: NCT05520814
Drug: PD-1 inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg \* q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
Study: NCT03649321
Drug: Bemcentinib
Normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
Study: NCT03649321
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
Study: NCT03649321
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
Study: NCT03649321
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
Study: NCT01259856
Drug: PEGASYS
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
Study: NCT01259856
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
Study: NCT01259856
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
Study: NCT01824043
Drug: intravitreal ranibizumab injections
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
Study: NCT00368017
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg once a day for 12 weeks
Study: NCT00078962
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV